President Donald Trump reclassified state-licensed medical marijuana from Schedule I to Schedule III of the Controlled Substances Act [1].
This shift alters the legal landscape for medical cannabis by reducing the regulatory hurdles for scientists and lowering the tax burden for businesses. While the move provides significant relief for the industry and researchers, it does not fully legalize the use of marijuana at the federal level [1, 4].
The reclassification aims to ease scientific research restrictions and reduce tax burdens for dispensaries, citing the perceived medical benefits of cannabis [5]. By moving the substance to Schedule III, the administration acknowledges a lower potential for abuse compared to Schedule I substances—which are defined as having no currently accepted medical use—and recognizes a medical utility [1].
Reports on the timing of the order vary. One report said that an executive order was signed in the Oval Office on Dec. 18, 2025 [2]. Another report said that Acting Attorney General Todd Blanche signed the order on April 23, 2026 [3].
Despite the change in classification, the drug remains controlled. The shift does not legalize recreational or medical use federally, though it does ease research and tax constraints [4]. Additionally, the administration has ordered agencies to quickly ease restrictions on marijuana and increase the availability of CBD [5].
The move follows a trend of increasing state-level acceptance of medical cannabis, creating a long-standing conflict between state laws and federal prohibitions. This administrative action represents a partial alignment of federal policy with those state-level realities.
“The shift does not legalize recreational or medical use federally, but eases research and tax burdens”
The reclassification to Schedule III is a significant regulatory pivot that acknowledges the medical utility of cannabis without removing it from the Controlled Substances Act entirely. By lowering the schedule, the U.S. government reduces the '280E' tax penalty that has historically hindered cannabis businesses and removes the most stringent barriers to clinical research. However, because the drug is not fully descheduled or legalized, a legal gray area persists between federal law and state-licensed operations.
